2182 results about "Virology" patented technology

The invention provides an RNA polymerase variant and application thereof, and relates to the technical field of biology. Wild type T7 RNA polymerase is modified to obtain the T7 RNA polymerase variant, the enzyme specific activity of the T7 RNA polymerase variant is remarkably improved compared with that of the wild type T7 RNA polymerase, the addition amount of the polymerase in the in-vitro transcription reaction process can be reduced, and the cost is saved; in addition, the mutant also effectively reduces the generation of incomplete fragment impurities, and the mRNA integrity is significantly improved to 99%. The invention further provides a method for preparing RNA through in-vitro transcription.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The invention provides a group of monoclonal antibody pairs targeting adenovirus DBP protein, the monoclonal antibody pairs comprise a capture antibody and a detection antibody, each of the two antibodies comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, and the capture antibody and the detection antibody are used for capturing and detecting the adenovirus DBP protein. Wherein the capture antibody is a monoclonal antibody 19E3; and the detection antibody is selected from a monoclonal antibody 96 to 10D8, a monoclonal antibody 95 to 2B7, a monoclonal antibody 96 to 2C10, a monoclonal antibody 96 to 8E10, a monoclonal antibody 96 to 13D5 or a monoclonal antibody 96 to 2B10. The monoclonal antibody pair disclosed by the invention can be used for efficiently detecting various types of HAdV DBP.

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The invention discloses dsRNA of a targeted BdSpt7 gene, a biocontrol agent and application of the dsRNA. The sequence of the dsRNA of the targeted BdSpt7 gene is as shown in SEQ ID No.2. The invention further discloses a preparation method of the biocontrol agent of the targeted BdSpt7 gene. The active ingredient of the biocontrol agent is the dsRNA of the target BdSpt7 gene. The invention also provides an application of the botryosphaeria dothidea BdSpt7 gene in prevention and treatment of apple botryosphaeria dothidea, and a nucleotide sequence of the botryosphaeria dothidea BdSpt7 gene is shown as SEQ ID No.1. The invention also provides an African trichoderma harzianum engineering strain for expressing dsRNA, the African trichoderma harzianum engineering strain is integrated with a dsRNA expression box for interfering gene expression of a target gene BdSpt7, the dsRNA expression box is shown as SEQ ID No.1, and the African trichoderma harzianum is an African trichoderma harzianum with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 41709. The dsRNA targeting the BdSpt7 gene can significantly reduce the pathogenicity of the physalospora piricola through interference, and the African trichoderma harzianum engineering strain can colonize on the plant surface and continuously express the dsRNA so as to play a role in preventing and treating the physalospora piricola, and is green and environment-friendly.

The present invention is directed to a modified HSV-1 vector comprising at least two transgenes that exhibit controllable and distinct kinetics of expression, a pharmaceutical composition thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto.

The invention discloses a primer group for subspecies typing of mycobacterium abscessus and an analysis method, and belongs to the technical field of pathogenic microorganism detection. Wherein the primer group comprises 14 primers with sequences shown as SEQ ID NO.1-14, the 14 primers totally correspond to 7 target areas of abscess subspecies, marssai subspecies and boleia subspecies in a mycobacterium abscessus complex, and the identification of the three subspecies can be realized by identifying mutation sites in the target areas through sequencing. According to the method, the subspecies of the mycobacterium abscessus complex group can be rapidly and effectively identified, and a reliable means is provided for clinical accurate detection.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting feline coronavirus NP protein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 3C6 and 6H9, 3C6 serves as a coating antibody, 6H9 is used for colloidal gold labeling, and efficient and specific sandwich detection of feline coronavirus NP protein can be achieved. According to the invention, the monoclonal antibody combination is correspondingly applied to an immunodetection platform, and a rapid detection test strip or test paper card based on a colloidal gold immunochromatography technology is constructed. The test paper has high sensitivity to FECV-NP and FIBV-NP recombinant proteins, has no cross reaction with other proteins, and is suitable for rapid and on-site detection.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

A major challenge in the field of antibody-based therapeutics is the development of antibodies that have longer duration of action, longer half-life and can be delivered to a patient at lower doses. The current methods to achieve this aim depend on the engineering modification of the pH-dependent antigen binding properties of the antibodies, which is very strenuous and generally requires further optimization of the pH-sensitive interactions in a low-throughput, individualized manner because these methods depend mainly on the introduction of histidine mutations in specific antibody complementarity determining regions (CDRs). In the present invention, the inventors provide antibodies and other antigen-binding proteins that carry mutations outside of the complementals, thereby conferring universal pH-sensitive binding properties to the antibodies. The invention also relates to methods of isolating and generating said antigen binding proteins, compositions and medical uses thereof.

The invention discloses a kit, an antibody and a method for detecting A-type botulinum toxin hemagglutinin-70. The kit of the present invention comprises an antibody capable of targeting type A botulinum toxin hemagglutinin-70. The antibody disclosed by the invention has good affinity and stability, can be widely applied to detection of A-type botulinum toxin hemagglutinin-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detecting botulinum toxin component antibodies, and provides a quality control means for commercialized and self-researched antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting Inhibin βE (INHBE). Such compounds are useful in methods for reducing expression of INHBE and for therapeutically treating INHBE associated diseases, disorders and / or conditions, or symptoms thereof in a subject.

The invention provides an RNA (Ribonucleic Acid) polymerase variant and a preparation method thereof, and an RNA product with low dsRNA pollution can be obtained by applying the RNA polymerase variant disclosed by the invention to in-vitro transcription. In addition, the invention further provides a method for preparing RNA through in-vitro transcription.

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The invention relates to a monoclonal antibody targeting RSV F protein, and a related product and application thereof. The monoclonal antibody (AD5) or the antigen binding fragment of the monoclonal antibody is specifically bound with the Site III antigen epitope of the RSV F protein. The antibody AD5 disclosed by the invention has the characteristics of targeting high-conservative epitope (Site III) and having high neutralizing activity, and overcomes the main defect that the neutralizing activity is not high when the existing listed antibody targets the high-conservative epitope.

According to the trace pathogen enrichment device and the detection method provided by the invention, pathogen products separated from uncultured samples extracted by using the device can be subjected to drug sensitivity test after simple culture and bacteria collection treatment, so that the culture process is shortened compared with pathogen diagnosis and identification of clinical infected samples, a drug sensitivity result can be obtained more quickly, and the detection efficiency is improved. And a more timely diagnosis and treatment reference is provided for clinicians.

The present disclosure relates to polypeptides comprising an antigen fragment of the receptor binding domain (RBD) of coronavirus spike glycoprotein, protein nanostructures thereof, methods of manufacture thereof, and prophylactic and therapeutic uses thereof. In various aspects, the antigen fragment comprises a coronavirus subdomain 1 (SD1).

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The invention belongs to the technical field of biology, and relates to an RNA polymerase variant, and when the RNA polymerase variant is applied to in-vitro transcription, an RNA product with low dsRNA pollution can be obtained. In addition, the invention further provides a method for generating RNA through in-vitro transcription.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.

The disclosure relates generally to canine antibody variants and uses thereof. Specifically, the disclosure relates to mutations in the constant region of canine antibody for improving its half-life and other characters.

The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).

The present invention provides a bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, the bacteriophage having a genome containing a nucleic acid sequence represented by the genome of the bacteriophage specified by the preservation number NITE BP-03513 or NITE BP-03514 or the preservation number NITE BP-03918, the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, and the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis. The capsid of the phage is connected with the cell-penetrating peptide through a tag.

The present invention relates to chimeric promoters without CpG motifs. The chimeric promoter comprises a CMV enhancer, an IFN-gamma gene core promoter and an intron sequence, and a CG motif in the CMV enhancer, the IFN-gamma gene core promoter and the intron sequence is subjected to substitution mutation. The promoter can improve the expression efficiency of exogenous genes in activated immune cells.

The present invention relates to the technical field of biology, and specifically relates to a primer set and the use thereof in the preparation of a thalassemia detection kit. The primer set comprises primers designed on the basis of at least one of sequences 1)-13): 1) chr16:219267-219290; 2) chr16:228804-228829; 3) chr16:215255-215276; 4) chr16:235945-235971; 5) chr16:196488-196508; 6) chr11:5276986-5277008; 7) chr11:5257290-5257314; 8) chr11:5249915-5249939; 9) chr11:5258978-5259000; 10) chr11:5221888-5221912; 11) chr11:5189975-5189996; 12) chr11:5152341-5152365; 13) chr11:5133905-5133925, wherein the primers are at least partially complementary to sequences 1)-13).

The present application relates to the field of microbiological technology, and particularly relates to a pathogenic bacterium causing root rot symptoms of red heart disease of Astragalus membranaceus and application thereof, the pathogenic bacterium is Fusarium sp. Fusarium sp. FUS-001-2025, preserved in China General Microbiological Culture Collection Center on March 16, 2026, with the preservation number of CGMCC No. 42529; it is determined to be a new recorded strain of Fusarium sp. through morphological and molecular identification, and the bactericide sensitivity determination shows that 25% silthiofam·prochloraz has the strongest inhibition effect, 25% bromothalonil, 50% azoxystrobin and 70% methylthiophanate have significant inhibition at high concentrations. The present application provides an important pathogenic bacterium resource for the pathogenic mechanism, disease resistance evaluation and development of control agents of red heart disease of Astragalus membranaceus.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and / or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.